31 commercial payer policies list J1931. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
31 policies from 15 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Status of J1931 |
|---|---|---|
| Aldurazyme (laronidase) | Not recorded | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Aldurazyme (laronidase) | Jun 1, 2025 | Prior auth requiredInferred from policy title |
| Aldurazyme (laronidase) | Jun 1, 2024 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Laronidase (Aldurazyme) | Jul 1, 2023 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Laronidase (Aldurazyme) | Aug 1, 2021 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Laronidase (Aldurazyme) | Jan 1, 2019 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Laronidase (Aldurazyme) | Jul 1, 2022 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Laronidase (Aldurazyme) | Oct 1, 2019 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Laronidase (Aldurazyme) | Sep 1, 2020 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Policy | Effective | Status of J1931 |
|---|---|---|
| Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme, Elaprase, Vimizim, Naglazyme, Mepsevii, etc.) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme, Elaprase, Vimizim, Naglazyme, Mepsevii, etc.) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J1931 |
|---|---|---|
| Enzyme-Replacement Therapy for Lysosomal Storage Disorders | Oct 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J1931 |
|---|---|---|
| Enzyme-Replacement Therapy for Lysosomal Storage Disorders | Oct 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J1931 |
|---|---|---|
| Enzyme-Replacement Therapy for Lysosomal Storage Disorders | Oct 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J1931 |
|---|---|---|
| Enzyme-Replacement Therapy for Lysosomal Storage Disorders | Oct 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J1931 |
|---|---|---|
| Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme, Elaprase, Vimizim, Naglazyme, Mepsevii, etc.) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Enzyme Replacement Therapy for Mucopolysaccharidosis (e.g., Aldurazyme, Elaprase, Vimizim, Naglazyme, Mepsevii, etc.) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J1931 |
|---|---|---|
| Medical Therapies for Enzyme Deficiencies | Oct 1, 2026 | Covered |
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Policy | Effective | Status of J1931 |
|---|---|---|
| Medical Therapies for Enzyme Deficiencies | Oct 1, 2026 | Covered |
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Policy | Effective | Status of J1931 |
|---|---|---|
| Laronidase Aldurazyme | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J1931 |
|---|---|---|
| Laronidase (Aldurazyme) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J1931 |
|---|---|---|
| Laronidase (Aldurazyme); CP.PHAR.152 | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J1931 |
|---|---|---|
| Laronidase (Aldurazyme), Galsulfase (Naglazyme), and Idursulfase (Elaprase), Elosulfase alfa (Vimizim), and Vestronidase alfa (Mepsevii) | Sep 11, 2020 | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J1931 |
|---|---|---|
| Aldurazyme (laronidase) Listed in Moda Health's provider indexes for Oregon, Alaska, Idaho, Texas. The document does not establish the member's state or line of business. | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J1931 |
|---|---|---|
| Medical Therapies for Enzyme Deficiencies | Oct 1, 2026 | Covered |